key: cord-0703897-5xzjiuee
authors: Tegethoff, Sina A.; Danziger, Guy; Kühn, Dennis; Kimmer, Charlotte; Adams, Thomas; Heintz, Lena; Metz, Carlos; Reifenrath, Katharina; Angresius, Rebecca; Mang, Sebastian; Rixecker, Torben; Becker, André; Geisel, Jürgen; Jentgen, Christophe; Seiler, Frederik; Reichert, Matthias C.; Fröhlich, Franziska; Meyer, Sascha; Rissland, Jürgen; Ewen, Sebastian; Wagenpfeil, Gudrun; Last, Katharina; Smola, Sigrun; Bals, Robert; Lammert, Frank; Becker, Sören L.; Krawczyk, Marcin; Lepper, Philipp M.; Papan, Cihan
title: TRAIL, IP-10, and CRP in predicting the progression of SARS-CoV-2 infection: A prospective, cohort study
date: 2022-05-25
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.05.051
sha: 7968d2c46dd3dd9794c77a3766e5ba99d4b1dcb1
doc_id: 703897
cord_uid: 5xzjiuee

Background : Early prognostication of COVID-19 severity will potentially improve patient care. Biomarkers such as TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein (CRP) might represent possible tools for point-of-care-testing and severity prediction. Methods : In this prospective cohort study we analysed serum levels of TRAIL, IP-10, and CRP in COVID-19 patients, compared them to control subjects, and investigated association with disease severity. Results : A total of 899 measurements were performed in 132 patients (mean age 64 years, 40.2% females). Among COVID-19 patients,TRAIL levels were lower (49.5 vs. 87 pg/mL p=0.0142), while IP-10 and CRP showed higher levels (667.5 vs. 127 pg/mL, p<0.001; 75.3 vs. 1.6 mg/L, p<0.001) as compared to healthy controls. TRAIL yielded an inverse correlation with length of hospital and ICU stay, SAPS II and NEWS scores, and IP-10 showed a positive correlation with disease severity. Multivariate regression revealed that obesity (adjusted odds ratio 5.434, 95% confidence interval 1.005-29.38), CRP (aOR 1.014, 95%CI 1.002-1.027), and peak IP-10 (aOR 1.001, 95% CI 1.00-1.002) were independent predictors of in-ICU mortality. Conclusions : We demonstrated a correlation between COVID-19 severity and TRAIL, IP-10, and CRP. Multivariate regression showed a role for IP-10 in predicting unfavourable outcome, i.e. in-ICU mortality. Trial registration : Clinicaltrials.gov, NCT04655521

After almost two years into the pandemic, coronavirus disease 2019 (COVID-19) still poses an imminent global threat (Meyer et al., 2020) . As of April 2022, 6.1 million people have died from or with an infection of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) (https://coronavirus.jhu.edu/, accessed April 2022) worldwide. With vaccination campaigns running slow (Papan et al., 2021b) , increasing numbers of vaccine breakthrough infections, and a surge of variants of concern with possible immunevasion (Juthani et al., 2021) , the pandemic will most likely continue until the most dominant variant(s) eventually become endemic (Boehm et al., 2021) .

While most infections remain asymptomatic or cause only mild symptoms, severe cases are still causing significant morbidity and mortality (Serafim et al., 2021) . Such patients would benefit from early detection of risk factors for an unfavourable outcome in order to implement monitoring and initiate promising therapeutic approaches (Ghosn et al., 2021; REMAP-CAP Investigators et al., 2021; Rosas et al., 2021) .

Based on current knowledge, hyperinflammation plays a critical role in disease progression and clinical deterioration (Thurner et al., 2021) suggesting that measurements of immunebased biomarkers represent promising tools for the early detection of likelihood to deteriorate (Abers et al., 2021; Arnold et al., 2021; Vassallo et al., 2020) . Since results for some of these parameters can be available within minutes through point-of-care testing, the insights provided by immune biomarkers might facilitate and accelerate diagnostic work-up (Clark et al., 2020) . Ultimately, they have the potential to guide therapeutic decisions which may lead to improved patient care and appropriate allocation of resources in return.

A novel platform (MeMed Key ® ) measures the circulating levels of the three host response immune proteins TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10) and C-reactive protein (CRP). It was initially established to distinguish between a bacterial and viral aetiology of infection (Oved et al., 2015; Papan et al., 2021a) , however, recent studies have demonstrated a wider range of application. For example Lev et al. showed that IP-10 may assist in clinical decision making in patients with COVID-19 by flagging the inflammatory response (Lev et al., 2021) . This is of particular interest, since TRAIL and IP-10 are virally induced markers, and especially interferon-mediated response is critical in severe viral infections (Papan et al., 2014) , as reported also for severe courses of COVID-19 (Bastard et al., 2021 van der Wijst et al., 2021; Zhang et al., 2020) .

In this study (DIRECTOR), we aimed to evaluate the different serum levels of host-immune biomarkers including TRAIL, IP-10 and CRP in COVID-19 patients and to analyse their association with disease severity.

The DIRECTOR (Dynamics of the immune response to COVID-19 / infection by SARScoronavirus-2) study was a prospective, observational cohort study at the Saarland University Medical Centre in Homburg, southwest Germany. After signed informed consent (by patients or their legal guardians), patients (age 3 months and older) meeting the following inclusion criteria were enrolled: PCR-confirmed infection with SARS-CoV-2 (except for controls) during the second and third pandemic wave experienced in Germany (December 2020 to July 2021). Results for patients under the age of 18 years were analysed separately and are not reported herein. To increase the sample size, patients from the first COVID-19 wave between March and May 2020 were included retrospectively.

Control subjects were recruited mainly among the hospital staff, and were divided into two groups: healthy controls (Group 1) and adults with symptoms of acute respiratory tract infection (Group 2), both having negative SARS-CoV-2 PCR tests.

Approval of the local ethical committee was obtained (Ärztekammer des Saarlandes, reference number 019/20) and the study was registered at clinicaltrials.gov (NCT04655521).

Reporting of this study adhered to the STROBE guidelines for reporting observational cohort studies (Supplementary Table S1 ).

Nasopharyngeal swabs, blood samples and SARS-CoV-2 RT-PCR were routinely performed on admission and regularly throughout the hospital stay to account for dynamic changes in biomarker levels over time. For performing host signature measurements, an additional serum tube was obtained.

The National Early Warning Score (NEWS) was generated for every participating patient presenting to the Emergency Department in order to objectify COVID-19 disease severity on admission. For comparability of the patient's health status in the intensive care unit (ICU), we generated the Simplified Acute Physiology Score II (SAPS II) for each in-ICU day where biomarker measurements were performed. Furthermore, we conducted a follow-up telephone interview with the participants after hospital discharge. Questions included the ongoing presence of COVID-19 related symptoms and additional visits to the general practitioner due to ongoing symptoms.

Levels of TRAIL, IP-10, and CRP were measured at the study site in serum samples. After being centrifuged for 20 minutes at 4000 RPM and 20°C in a Rotixa 50 RS centrifuge, samples were measured within the next hour or intermittently frozen at -20°C. Measurements were performed on a MeMed Key® (MeMed Diagnostics, Tirat Carmel, Israel) according to the manufacturer's instructions for use. The method is based on a chemiluminescent immunoassay (CLIA). The platform was placed at the central lab due to logistics, but is suitable for point-of-care testing.

To examine the levels of biomarkers including TRAIL, IP-10, and CRP in COVID-19 patients as compared to healthy controls or patients with respiratory infection but testing SARS-CoV-2 negative, we compared each first measurement of our study population to both control groups. For assessment of the correlation between biomarker serum levels and disease severity, we evaluated the minimal and maximal (or peak) levels shown throughout the hospital stay for each patient as well. Defining parameters of disease severity were ICU admission, need for mechanical ventilation and in-ICU mortality.

Further analyses included analyses regarding severity levels on admission and the prognosticating value of biomarkers to predict disease progression. Separate subgroup analyses on patients with early biomarker measurements (within 24h of hospital admission) were conducted. To address a potential bias, we compared IP-10 levels of patients with cancer to all other COVID-19 patients. Variables are reported as the median with interquartile range (IQR) or as the mean with standard deviation (s). Group comparisons were performed using t-test and Mann-Whitney U test for continuous variables, and Fisher's exact test and chi-square for categorical variables. Correlation between biomarkers and continuous variables accounting for clinical severity such as duration of hospital stay and ICU days as well as correlation with other laboratory parameters was evaluated with Spearman's rank test. Univariate and multivariable logistic regression models were developed to detect biomarkers and other variables associated with clinical severity. We performed Kaplan-Meier analyses to assess the association of biomarker levels with the outcome variables implementation of mechanical ventilation and in-ICU death. We performed analyses using GraphPad Prism (Version 9.0.0) and SPSS (Version 28.0). The statistical significance level was set at 0.05.

Overall, 172 eligible patients were approached to participate in the DIRECTOR study. Of these, 30 patients declined participation and in ten patients measurements were invalid due to technical error, resulting in a total study population of 132 patients ( Figure 1 ).

The mean age was 64 years, ranging from 23 to 98, with 53 (40.2%) being female (Table 1) .

Overall, 109 patients (82.6%) showed COVID-19 related symptoms on admission, most commonly dyspnoea and fever. Only one patient remained in outpatient care after being tested positive for SARS-CoV-2. A total of 47 patients (35.6%) were admitted to the ICU, of whom 61.7% (n=29) required mechanical ventilation and 21.3% (n=10) were treated with extracorporeal membrane oxygenation (ECMO). In hospital mortality was 15.9% (21 patients).

Bacteria and fungi were detected in 47 and 10 COVID-19 patients, respectively. A subset of 99 patients (75%) received antibacterial treatment, whereas glucocorticoids (prednisone or dexamethasone) were administered to 38 patients (28.8% of the study population).

Remdesivir was prescribed to 16 patients (12.1%).

Telephone follow-ups were completed in 56 patients after hospital discharge. Among these patients, 24 (42.9%) stated to still suffer from COVID-19 related symptoms (e.g.dyspnoea, fatigue). Up to that time, 24 patients still required additional visits to their general practitioner.

A total of 899 measurements of host-immune biomarkers were performed in our study population, owing to an average of 6.8 measurements per patient. First measurements were conducted on average 4.5 days (s=6.455) after admission. The distribution of initial measurements over time is shown in Supplementary Figures S1 and S2.

The control group consisted of 27 adults (mean age 47.1 years, range 22-83; 19 (70.4%) females), composed of 19 adults in group 1 and 8 adults in group 2. The following symptoms of a respiratory tract infection were stated: sore throat n=4, cough n=3, fever n=1, chest pain n=1, other n=5.

In first measurements, there was a median TRAIL level of 49.5 pg/mL (IQR 68.25) in COVID-19 patients, while healthy adults (control group 1) attained a median level of 87 pg/mL (IQR 51). With a p-value of 0.0142, the results showed significance. Values of adults with symptoms (control group 2) ranged from 20 to 112 pg/mL with a median of 73.5 pg/mL (Supplementary Figure S3 When comparing controls (n=27) and COVID-19 patients, high IP-10 (odds ratio 1.007, p=0.001) and CRP (OR 1.144, p<0.001) serum levels were associated with a positive PCR test on SARS-CoV-2 in the univariate logistic regression model, with CRP remaining significant in the multivariate analysis (adjusted OR 1.112, p<0.001, Nagelkerke's R 2 0.703) (Extension of Table 2 , supplements).

Serum levels of TRAIL showed an inverse and of CRP a positive correlation with different parameters of disease severity. Regarding the first measurement, patients admitted to the ICU showed significantly lower TRAIL levels (p=0.0032). The median level was 35 pg/mL (IQR 52.7) whereas the median TRAIL level of patients remaining in the normal care unit (NCU) was 58 pg/mL (IQR 76) ( Figure 2A) . Furthermore, CRP levels were significantly higher in patients developing a severe course of the disease (p=0.0003 for ICU admission, p<0.001 for mechanical ventilation), comparing a median of 58.3 mg/L (IQR 101.8) and 58.3 mg/L (IQR 94.7) for non-severe with a median of 113.8 mg/L (IQR 118.3) and 149.2 mg/L (IQR 128.6) for severe COVID-19, respectively ( Figure 2C and F). There was no significant difference in these groups regarding initial IP-10 measurements ( Figure 2B and E).

Notably, low TRAIL levels on patients' first measurements also correlated with a longer a longer ICU stay (r= -0.6264, p<0.001) (Supplementary Figure S4) , and showed weak correlations with duration of hospital stay (r= -0.2532, p=0.0034) (Supplementary Figure S4) , and SAPS II-scores for patients in the ICU (r= -0.3713, p<0.001) ( Figure 3A ). In addition, we found a significant difference in minimal TRAIL levels (p<0.001) between patients who died in the ICU (n=13, median 17 pg/mL, IQR 26) compared to COVID-19 survivors in the NCU, (n=77, median 41 pg/mL, IQR 40) ( Figure 4A ). Minimal TRAIL levels were found on average 8.08 days (s=8.171) after hospital admission, and on average 19 days (s=22) before demise for in ICU deceased patients.

Examining maximal IP-10 levels, these were significantly higher in patients who later on deceased in the ICU compared to survivors in the NCU (p<0.001). Patients who later on deceased showed a median maximal level of 3295 pg/mL (IQR 3010) while survivors only had a median level of 909 pg/mL (IQR 1679) ( Figure 4B ). Maximal IP-10 levels were present on average 6.91 days (s=8.787) after admission and, regarding patients who died in the ICU, 21 days (s=24) before decease. Levels of all IP-10 measurements in the ICU (n=340) also showed a weak correlation with the SAPS II-score (r=0.1772, p=0.001) ( Figure 3B ). Of note, CRP levels, but not IP-10 levels, showed a significant correlation with length of hospital or ICU stay (Supplementary Figure S5 and S6). The dynamic changes of biomarker levels per patient are shown in the Supplemental Material ( Supplementary Figures 6-13 ). Of note, detailed analyses of intraindividual biomarker analyses (Supplementary Figures S13 and S14) showed that all deceased patients had very low TRAIL levels one day before demise.

In 58 patients who presented at the Emergency Department, first biomarker measurements were available within 24 hours of admission. A correlation of low levels of TRAIL with high NEWS-score results was shown for this subgroup (r= -0.4459, p=0.0012) ( Figure 5 ). We found no significant correlation between IP-10 and the NEWS-score (Supplementary Figure   S15 ).

Regarding the univariate logistic regression model, low initial TRAIL levels and male sex were associated with increased likelihood of required mechanical ventilation with an odds ratio of 0.976 (p=0.001) and 3.804 (p=0.012). This association was also found in Kaplan-Meier analysis, using a cut-off for initial TRAIL of 40 pg/mL, which yielded a significantly higher probability of mechanical ventilation in patients with initial TRAIL levels of <40 pg/mL (logrank test x 2 18.8, p<0.001) (Figure 6 ). In the multivariable logistic regression model, obesity (OR 14.311, ) and CRP (OR 1.014, 95%CI 1.005-1.024), significantly related to the clinical outcome mechanical ventilation (Table 2b) . For the outcome death in ICU, CRP and peak IP-10 were significant in the multivariable regression model (Table 2c) . IP-10 also yielded a significant difference in the Kaplan-Meier survival analysis for patients with peak IP-10 levels of >3000 pg/mL (logrank rest x 2 10.5, p=0.001) ( Figure 6 ).

Similarly, for the subgroup with early biomarker measurement (within first 24h), only obesity was associated with ICU admission (Table 2d) .

We found weak correlations of TRAIL and IP-10 levels on patients' first measurements with other laboratory parameters measured on the same day (Supplementary Table S2 ).

There was no statistically significant difference in initial IP-10 levels in COVID-19 patients with cancer (n=13, median 872 pg/mL, IQR 2299) and all other COVID-19 patients (n=119, median 631 pg/mL, IQR 1126, p=0.173).

In this study, we assessed the levels of TRAIL, IP-10, and CRP in patients with COVID-19, as well as their association with disease severity. We showed that IP-10 may be a valuable biomarker to detect patients with a higher mortality risk, alongside obesity and CRP. Low TRAIL levels related to a high NEWS-score on admission, which takes into account different vital parameters (respiratory rate, oxygen saturation, temperature, systolic blood pressure, heart rate) as well as level of consciousness and need for supplemental oxygen (Tirkkonen et al., 2019) . In addition, patients with an initial TRAIL level <40 pg/mL had a significant association with mechanical ventilation in the Kaplan-Meier analysis, and similarly low TRAIL levels were observed in patients who died. However, TRAIL failed to show a significant association with any of the adverse outcomes in the multivariate regression model. The discrepancies in the aforementioned analyses are explainable by the important role of the time factor in Kaplan-Meier analyses. Especially the correlation to a high NEWS-score and the results shown in the discussed Kaplan-Meier analysis highlight TRAIL's potential use for risk stratification in the Emergency Department. Since levels were extremely low in all patients shortly before demise, further exploration of TRAIL's capability for monitoring purposes seems reasonable as well. Even in COVID-19 survivors, the levels got lower the longer the hospital stay was. Accordingly, increasing IP-10 levels would be expected, but this could not be shown in our study.

For measurements in the ICU, a correlation of TRAIL and IP-10 with the SAPS II-Score was found. SAPS II-score results convert to the probability of hospital mortality (Le Gall et al., 1993) . These results confirm the findings of Chen and colleagues and Yang et al. regarding IP-10's association with disease severity Yang et al., 2020) .

Our revelations support the suitability of the analysed immune-based biomarkers TRAIL, IP-10, and CRP to be included in risk assessment models. Early detection of risk factors as well as of clinical deterioration may help in clinical decision making. Identifying patients at risk could reduce the administration of expensive monoclonal antibodies or antivirals in unnecessary cases as well as protect non-vulnerable patients from hospitalisation and invasive measures, both contributing to better patient outcome and better use of scarce resources.

Especially since a shift in the coming patient population is to be expected due to vaccination of individuals at high risk, patient characteristics (e.g., comorbidities, age, gender) should not be used as a sole tool for risk stratification even though male sex and obesity were independently associated with poor outcome in this and other studies (Palaiodimos et al., 2020; Simonnet et al., 2020) . Therefore, prediction models combining several variables and features seem reasonable.

During the past months, several studies evaluated different laboratory parameters for such purposes. D-dimers, ferritin, procalcitonin, lactate dehydrogenase (LDH) and serum amyloid A (SAA) are some examples of markers associated with poor prognosis of COVID-19, but their accuracy remains to be validated Li et al., 2020; Poggiali et al., 2020; Wang et al., 2021) . Since disease progression is most likely caused by hyperinflammation, application of cytokine measurements seems reasonable for prognosticating and monitoring COVID-19 patients (Juthani et al., 2021; Lev et al., 2021) . Del Valle et al. demonstrated that serum interleukin 6 (IL-6) and tumour necrosis factor α (TNF-α) outperformed other markers (Del Valle et al., 2020) . However, their specificity is uncertain, and cytokine quantification as well as clinically helpful interpretation remains challenging.

Additionally, correlation to the primarily analyzed biomarkers was weak in this study and measurement of multiple laboratory parameters comes across as impractical (Liu et al., 2021) . TRAIL, IP10, and CRP can be measured on a single immunoassay platform generating results within 15 minutes, overcoming these limitations. Especially their computational integration into a single numeric score is promising, with a novel clinical severity score currently being developed (Mastboim et al., 2021) . Previously, Tang et al. showed that plasma concentrations of IP-10 and MIG were associated with poor clinical outcome already in SARS-CoV-1 in 2005. IP-10 even acted as an independent prognostic factor for adverse outcome (Tang et al., 2005) . COVID-19 appeared to be the main reason for elevated IP-10 levels in our patient population, since co-morbidities such as cancer showed no significant differences in group comparisons.

Either way, a critical examination and validation of a prediction model is paramount in avoiding more harm than good. Additionally, defining a baseline for these models is challenging since patients can present to the ED at different stages of the disease.

A limitation of our study is the low number of mild, outpatient COVID-19 cases including those who were asymptomatic, who usually did not present to the hospital. The overall cohort size may have impacted the relatively small effect sizes and the weak correlations reported herein. Furthermore, it is important to note that this study was conducted at a University hospital, thus creating a selection bias. Some patients were transferred here due to clinical deterioration, making it impossible to capture biomarkers and clinical data at an early stage of the disease in these patients. Thus, generalizability of the reported severity prediction needs further and external validation. Comparability between patients and controls is additionally hampered by the small sample size and the fact that controls were younger and more often female. Another limitation is that patients with a potentially bacterial co-infection were not separately assessed, as no adjudication process was included in the study to approximate disease aetiology as previously reported (van Houten et al., 2019; Papan et al., 2021a) . Further studies are warranted to investigate generalizability to other viral diseases, e.g., influenza. Besides, information about biomarker performance in vaccinated patients is lacking. Our choice in not giving a single definition for severe COVID-19 but rather demonstrating association of biomarkers to different parameters accounting for disease severity can be seen as a strength since definitions may shift in the future, but also as a weakness. In either case, further studies should externally validate the potential of TRAIL, IP-10, and CRP for predicting disease severity with definitions fully aligned to the WHO COVID-19 guidelines to allow categorization into more severity groups. Evaluation of the biomarker's capability for monitoring disease progression, co-infections, response to treatment, and selection of therapy could also bring an extra benefit. To verify the applicability of TRAIL, IP-10, and CRP for predicting COVID-19, further comparisons of serum levels to different infectious and non-infectious diseases would be helpful.

To conclude, TRAIL and IP-10 showed significant correlation with COVID-19 severity, and CRP and IP-10 levels were associated with adverse COVID-19 outcomes. This suggests that the inclusion of these markers into multivariable risk assessment models could be a promising tool in the management of COVID-19 patients.

All relevant data that support the findings of the study are available within the article.

Complementary data is available from the corresponding author upon reasonable request. Figure 1 . Flow diagram of the DIRECTOR study, conducted in Saarland, Germany, 2020/2021; study population comprising SARS-CoV-2 positive patients only.

Comparisons of (A) first TRAIL measurements, (B) first IP-10 measurements and (C) first CRP measurements between patients who were admitted to the ICU (=severe n=47) and patients who remained in the NCU n=85) . Further comparisons (D-F) regarding patients requiring mechanical ventilation (MV, n=29) and patients who did not (no MV, n=103 (A) Correlation of the "New Early Warning Score" of COVID-19 patients presenting to the hospital's Emergency Department with initial TRAIL measurements conducted less than 24 hours after admission (n=50). Significance level, spearman correlation coefficient (r) and simple linear regression line are shown. (B) Comparison of initial TRAIL levels (measurements conducted less than 24 hours after admission) between patients presenting to the Emergency Department with a NEWS-Score lower than 5 (n=27) and patients with a NEWS-Score of 5 or higher (n=23). The black line denotes the median of each group. The box identifies values between 25 and 75 percentiles whereas the whiskers indicate minimal and maximal serum levels. P-values are defined as follows: ns: non-significant, *: p≤0.05, **: p≤0.01, ***: p≤0.001 Figure 6 . Kaplain-Meier analyses of (A) the relation between initial TRAIL with cutoff 40 pg/mL for the outcome variable mechanical ventilation, and (B) the relation between maximal IP-10 cutoff 3000 pg/mL and death in ICU (maximum set at 100 days). Percentages only refer to the number of patients for whom the Follow Up Interview was completed c Death occurred in these patients without ICU admission due to an existing patient decree Table 2 . Results of univariate and multivariable logistic regression analyses of the patient cohort recruited within the DIRECTOR Study, Saarland, Germany, 2020/2021. TRAIL, IP-10, and CRP indicate first measurements unless specified otherwise. Significant results are highlighted in bold (+ grey shaded cells for aOR). OR: Odds Ratio (univariate), aOR: adjusted Odds Ratio (multivariate), CI: Confidence interval a) All COVID-19 survivors (n=111) as well as in ICU deceased COVID-19 patients (n=13), Admission to ICU (n=47), Nagelkerke's R 2 0.404 b) All COVID-19 survivors (n=111) as well as in ICU deceased COVID-19 patients (n=13), Need for mechanical ventilation (n=29), Nagelkerke's R 2 0.538 c) All COVID-19 survivors (n=111) as well as in ICU deceased COVID-19 patients (n=13), Deceased in ICU (n=13), Nagelkerke's R 2 0.485 d) Subgroup of patients with first measurements <24h after admission (n=58), Admission to ICU (n=10), Nagelkerke's R 2 0.460 

An immunebased biomarker signature is associated with mortality in COVID-19 patients

Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study

Preexisting autoantibodies to type I IFNs underlie critical COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Novel SARS-CoV-2 variants: the pandemics within the pandemic

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19

An inflammatory cytokine signature predicts COVID-19 severity and survival

Interleukin-6 blocking agents for treating COVID-19: a living systematic review

Expert panel diagnosis demonstrated high reproducibility as reference standard in infectious diseases

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Hospitalisation among vaccine breakthrough COVID-19 infections

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19

Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis

Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review

An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome

A global health perspective on SARS-CoV-2-hazards, disaster and hope

A novel host-proteome signature for distinguishing between acute bacterial and viral infections

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study

Beneficial IFN-α treatment of tumorous herpes simplex blepharoconjunctivitis in dedicator of cytokinesis 8 deficiency

COVID-19: fighting the foe with Virchow

Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2

Requiring Invasive Mechanical Ventilation

Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome

Autoantibodies against Progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill

National early warning score (NEWS) and the new alternative SpO2 scale during rapid response team reviews: a prospective observational study

Patients with Covid-19 exhibit different immunological profiles according to their clinical presentation

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19